- Home
- VRAX vs PAVM Comparison
VRAX vs PAVM Comparison
Compare VRAX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- PAVM
- Stock Information
- Founded
- VRAX 2013
- PAVM 2014
- Country
- VRAX United Kingdom
- PAVM United States
- Employees
- VRAX N/A
- PAVM N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PAVM Medical/Dental Instruments
- Sector
- VRAX Health Care
- PAVM Health Care
- Exchange
- VRAX Nasdaq
- PAVM Nasdaq
- Market Cap
- VRAX 7.3M
- PAVM 8.0M
- IPO Year
- VRAX 2022
- PAVM 2016
- Fundamental
- Price
- VRAX $1.87
- PAVM $0.79
- Analyst Decision
- VRAX
- PAVM Strong Buy
- Analyst Count
- VRAX 0
- PAVM 1
- Target Price
- VRAX N/A
- PAVM $19.00
- AVG Volume (30 Days)
- VRAX 304.3K
- PAVM 248.8K
- Earning Date
- VRAX 02-05-2025
- PAVM 03-25-2025
- Dividend Yield
- VRAX N/A
- PAVM N/A
- EPS Growth
- VRAX N/A
- PAVM N/A
- EPS
- VRAX N/A
- PAVM 0.53
- Revenue
- VRAX $84,872.00
- PAVM $4,034,000.00
- Revenue This Year
- VRAX $5,169.18
- PAVM $52.90
- Revenue Next Year
- VRAX $66.97
- PAVM $248.84
- P/E Ratio
- VRAX N/A
- PAVM $1.50
- Revenue Growth
- VRAX 7.03
- PAVM 166.27
- 52 Week Low
- VRAX $0.60
- PAVM $0.57
- 52 Week High
- VRAX $9.00
- PAVM $3.50
- Technical
- Relative Strength Index (RSI)
- VRAX 48.66
- PAVM 60.82
- Support Level
- VRAX $1.65
- PAVM $0.73
- Resistance Level
- VRAX $2.10
- PAVM $0.90
- Average True Range (ATR)
- VRAX 0.22
- PAVM 0.08
- MACD
- VRAX 0.01
- PAVM 0.02
- Stochastic Oscillator
- VRAX 42.47
- PAVM 65.02
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.